Compound: Trospium
SMILES: O=C(O[C@@H]1C[C@H]2[N+]3(CCCC3)[C@@H](C1)CC2)C(O)(c4ccccc4)c5ccccc5
InChIKey: OYYDSUSKLWTMMQ-JKHIJQBDSA-N
Synonyms: Trospium, Trospium cation, 47608-32-2, Trospium ion, UNII-T4Y8ORK057, T4Y8ORK057, Regurin, 3alpha-Hydroxyspiro(1alphah,5alphah-nortropane-8,1'-pyrrolidinium) benzilate, Flotros, [(1S,5R)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate, NCGC00167438-01, NCGC00167438-02, tropsium cation, tropsium ion, Regurin xl, TROSPIUM [VANDF], TROSPIUM [WHO-DD], SCHEMBL119810, SCHEMBL2447242, CHEMBL1888176, CHEBI:145791, BDBM50540489, DB00209, PD040367, NS00098770, [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate, AB01274814-01, AB01274814_02, BRD-K69469734-003-02-5, 3.ALPHA.-HYDROXYSPIRO(1.ALPHA.H,5.ALPHA.H-NORTROPANE-8,1'-PYRROLIDINIUM) BENZILATE, (1alpha,3beta,5alpha)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], (1S,3R,5R)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8lambda(5)-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium, SPIRO(8-AZONIABICYCLO(3.2.1)OCTANE-8,1'-PYRROLIDINIUM), 3-((HYDROXYDIPHENYLACETYL)OXY)-, (1.ALPHA.,3.BETA.,5.ALPHA.)-
Theoretical properties:
molecular_formula: C25H30NO3+
molecular_weight: 392.5 g/mol
exact_mass: 392.22256882 g/mol
formal_charge: 1
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 5
heavy_atom_count: 29
topological_polar_surface_area: 46.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Trospium is a carboxylic ester resulting from the formal condensation of the carboxy group of hydroxy(diphenyl)acetic acid with the hydroxy group of (1S,3R,5R)-3-hydroxy-85-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium. Its chloride salt is used to treat overactive bladder. It has a role as a muscarinic antagonist and an antispasmodic drug. It is a tertiary alcohol, a carboxylic ester, a quaternary ammonium ion and an azabicycloalkane.", "chebi": "A carboxylic ester resulting from the formal condensation of the carboxy group of hydroxy(diphenyl)acetic acid with the hydroxy group of (1<i>S</i>,3<i>R</i>,5<i>R</i>)-3-hydroxy-8\u03bb<small><sup>5</small></sup>-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium. Its chloride salt is used to treat overactive bladder.", "chembl": "TROSPIUM is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. It contains xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist. Xanomeline is a functionally-preferring muscarinic acetylcholine receptor M4 and M1 receptor agonist. Trospium chloride is a peripherally-acting non-selective muscarinic antagonist.\nThe most common side effects of xanomeline/trospium chloride include nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia (increased heartbeat), dizziness, and gastroesophageal reflux.\nIn September 2024, it was approved for medical use in the United States. It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. The FDA considers it to be a first-in-class medication. Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects. Xanomeline's mechanism of action in this context is hypothesized to be via modulating certain neurotransmitter circuits, including acetylcholine, dopamine, and glutamate, which can provide therapeutic benefits in schizophrenia and related conditions."}